Enasidenib, an Inhibitor of Mutant IDH2 Proteins, Induces Durable Remissions in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Leukemia - United Kingdom
doi 10.1038/s41375-019-0472-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Enasidenib-Induced Eosinophilic Differentiation in a Patient With Acute Myeloid Leukaemia With IDH2 and U2AF1 Mutations

British Journal of Haematology
Hematology
2018English

Combination Treatment of an IDH1 Inhibitor With Chemotherapy in IDH1 Mutant Acute Myeloid Leukemia

Annals of Hematology
MedicineHematology
2020English

Challenges in Treating Older Patients With Acute Myeloid Leukemia

Journal of Oncology
Oncology
2010English

How I Treat Older Patients With Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2018English

Enasidenib in Acute Myeloid Leukemia: Clinical Development and Perspectives on Treatment

Cancer Management and Research
Oncology
2019English

Acute Myeloid Leukemia in Patients Older Than 60 Year

Journal of Tumor Medicine & Prevention
2018English

Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients <= 60 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Decitabine Compared With Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness

Advances in Hematology
Hematology
2015English

Healthcare Resource Utilization in a Phase 3 Study of CPX-351 in Patients With Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia

Journal of Medical Economics
Health Policy
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy